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Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) is a virion-associated regulatory
protein that functions at several points within the viral life cycle and has been shown to accumulate primarily in
the nucleus and at the nuclear envelope. However, most studies have investigated Vpr localization employing cell
types irrelevant to HIV-1 pathogenesis. To gain a better understanding of how cellular phenotype might impact
HIV-1 Vpr intracellular localization, Vpr localization was examined in several cell lines representing major cellular
targets for HIV-1 infection within the peripheral blood, bone marrow, and central nervous system (CNS).
Results: Utilizing a green fluorescent protein-tagged Vpr, we detected Vpr mainly in foci inside the nucleus, at the
nuclear envelope, and around the nucleoli, with dispersed accumulation in the cytoplasm of human endothelial
kidney 293T cells. No differences were observed in Vpr localization pattern with respect to either the location of the
tag (N- or C-terminus) or the presence of other viral proteins. Subsequently, the Vpr localization pattern was explored
in two primary HIV-1 target cells within the peripheral blood: the CD4
+ T lymphocyte (represented by the Jurkat CD4
+ T-cell line) and the monocyte-macrophage (represented by the U-937 cell line). Vpr was found primarily in speckles
within the cytoplasm of the Jurkat T cells, whereas it accumulated predominantly intranuclearly in U-937 monocytic
cells. These patterns differ from that observed in a bone marrow progenitor cell line (TF-1), wherein Vpr localized
mainly at the nuclear envelope with some intranuclear punctuate staining. Within the CNS, we examined two
astroglioma cell lines and found that Vpr displayed a perinuclear and cytoplasmic distribution.
Conclusions: The results suggest that the pattern of Vpr localization depends on cellular phenotype, probably
owing to interactions between Vpr and cell type-specific host factors. These interactions, in turn, are likely coupled
to specific roles that Vpr plays in each cell type within the context of the viral life cycle. Phenotype-specific Vpr
localization patterns might also provide an explanation with respect to Vpr secretion or release from HIV-1-infected
cells within the peripheral blood and CNS.
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Background
Human immunodeficiency virus type 1 (HIV-1) viral pro-
tein R (Vpr) is a multifunctional virion-associated acces-
sory protein [1,2]. In general, Vpr functions early during
postentry steps [3] and as a de novo synthesized protein
following integration of the proviral DNA genome.
Following viral entry, Vpr participates as a component of
the preintegration complex, in the transport of the
reverse-transcribed viral genome to the nucleus [4], and
after nuclear import [5] Vpr likely plays a key role in regu-
lating immediate-early HIV-1 gene expression from the
integrated proviral template prior to the transition to Tat-
driven gene expression [6,7] .T h er o l eo fV p ra l o n gt h e
viral replication cycle is critical in nondividing cells (such
as monocytes) [8-10], whereas it has been shown to be dis-
pensable in T-lymphocytic cells and other cell types [11].
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any medium, provided the original work is properly cited.Several reports have defined the role Vpr has in cell cycle
arrest at the G2/M phase and as an apoptotic-inducing
protein by promoting the formation of mitochondrial per-
meability transition pores in several types of cells [12-14].
The number of functions Vpr serves might depend on sev-
eral distinct factors, such as intracellular Vpr concentra-
tions, stage of infection and/or disease, route of entry, and
the availability of specific host cell factors.
In the past 20 years researchers have investigated the
role that specific amino acid residues play in conferring a
particular Vpr intracellular localization pattern [15-22].
Others have investigated how specific alterations in these
residues could affect functional properties of Vpr relative
to the viral life cycle at the single-cell level and/or overall
host pathogenesis and disease (reviewed in [23,24]). Most
of these studies have explored Vpr localization using dif-
ferent protein tags primarily in readily transfectable eukar-
yotic cell lines (summarized in Table 1). Vpr was detected
mostly inside the nucleus [17,25-27] or at the nuclear
envelope [16,18,21,28,29], although small amounts were
also detected within the cytoplasm. A recent report has
also demonstrated how posttransfection time might affect
the specific pattern of Vpr localization [27] under specific
conditions, suggesting that cellular proteins play an impor-
tant role with respect to the intracellular localization of
Vpr. In addition, Vpr was shown to shuttle between the
nucleus and cytoplasm, thus giving rise to a different pat-
tern of accumulation at different time points [20]. In this
respect, Sherman and coworkers demonstrated that a chi-
meric Vpr coupled to pyruvate kinase localized primarily
within the cytoplasm (owing to a longer dwell time in that
cellular compartment) but would accumulate in the
nucleus after blockage of a nuclear export receptor [20].
Vpr nuclear accumulation has been attributed to specific
leucine-rich regions within Vpr alpha helices [18], which
partially overlap with a reported nuclear export signal
[5,20,22,30]. These amino acid stretches have been shown
to be involved in Vpr shuttling between the nucleus and
cytoplasm.
Most of the studies published to date have examined the
pattern of Vpr localization and the protein signals involved
in guiding the compartmentalization of this important
viral protein in cellular targets that have only minimal
relevance to HIV infection and disease (primarily HEK
293T, HeLa, and COS-1 cells). Targets were likely selected
for experimental use on the basis of their high transfection
efficiency and ease of in vitro growth. Unfortunately, little
is known about Vpr localization pattern in cells predomi-
nantly targeted by HIV-1 during the course of disease.
Among these, CD4
+ T lymphocytes and cells of the mono-
ctye-macrophage lineage account for the majority of the
HIV-1-infected cells within the peripheral blood (PB) and
peripheral lymph nodes, tissues, and organs [31,32]. In
the central nervous system (CNS), microglia [33] and
perivascular macrophages [34,35] represent the most com-
monly encountered productively infected cells; astrocytic
cells are often infected but have an altered pattern of
virus-specific transcription and much lower levels of viral
production during the course of infection [36,37]. Neurons
are generally considered refractile to HIV-1 infection
[38,39] although they are prone to damage as a result of
the neurotoxic properties associated with many of the
virus-encoded proteins, including Vpr [29,31,40-42]. With
this in mind, the primary objective of this study was to
explore how Vpr localization patterns might be altered in
cell types representative of cellular targets naturally
encountered by HIV-1 during the course of disease. To
define how the cellular phenotype may impact Vpr locali-
zation pattern, six different human cell lines representative
of the main cellular targets for HIV-1 within the PB and
CNS were utilized in transient gene delivery and expres-
sion studies. For each cell line, transfection studies were
performed using a Zoanthus green fluorescently tagged
HIV-1 NL4-3 Vpr, and intracellular localization patterns
were subsequently determined by deconvolution immuno-
fluorescence microscopy. Cumulatively, these studies indi-
cate that cellular phenotype impacts the intracellular
localization of HIV-1 Vpr. The physical location of the tag
(either at the amino- or carboxyl-terminus) did not influ-
ence the pattern of Vpr accumulation within any of the
human cell types examined in these studies. The Vpr loca-
lization patterns in lymphocytic and promonocytic cell
lines were shown to be predominantly cytoplasmic and
intranuclear, respectively, and differed from that pre-
viously reported within HEK 293T cells [16,18,21,28]. In
contrast, in a bone marrow (BM) progenitor cell line Vpr
was shown to localize in a pattern similar to that pre-
viously observed in 293T cells. This pattern of localization
was also observed in two different astroglioma cell lines
representative of CNS astrocytes. These results suggest
that Vpr may utilize distinct cellular host factors (differen-
tially expressed in various cell types), which may be
responsible for the observed differences in intracellular
localization and may alter the functional properties of Vpr
within a given cellular compartment during the course of
HIV-1 disease. This study represents the first to examine
Vpr localization pattern in a spectrum of cell lines repre-
sentative of cellular phenotypes targeted by HIV-1 during
interaction with the human host.
Results
Vpr localization pattern in human 293T cells
Previous studies have examined localization patterns of
Vpr in full-length form, shorter cleaved forms, as Vpr
peptides, or as Vpr variants with alternative amino acid
residues at specific positions deemed important in guid-
ing Vpr nuclear localization (Table 1). The choice of the
cell type used for each localization study was often
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Cell type Tag system Tag end Other tagged proteins Time (h) Localization pattern Comments Ref
HeLa b-Gal C – 48 n [17]
HA N – 48 pn [21]
b-Gal C – 38 pn, pef
FLAG N – 24 n, pn, pef [18]
Untagged ––5 n, pn, pef VV infection [60]
Untagged –– 48 n [73]
GFP N PK 24 c [74]
EYFP N – 24/48/72 n/n, pef/pef Time-dependent Vpr localization [27]
C – 24/48/72 n, pef/n, pef/pef
FLAG N – 48 n [57]
GFP C – 18 pn [29]
GFP C – 18 n [16]
EGFP N – 24 n, pef [58]
C – pn
mCherry N – pn, pef
C – pn
EGFP N – 24 n, pef [26]
C – n, pn
HA N – n, pef
FLAG N IRES + GFP 36 n [75]
FLAG C PKA, 6His ? n [76]
120 n, pn Infection
EGFP N – 14 n, pef [25]
FLAG N – 48 pn, pef [59]
FLAG N GST (C) ? n Micro-injected [77]
GFP N – 24 n [78]
GFP N IRES 24 n Transduction [79]
FLAG, YFP N – 36, 48 n [80]
293T HA N – 24 n [15]
EGFP N – 24 n [27]
C – pn, pef
FLAG N – 48 pn [57]
GFP N – ? n, pn, pef [44]
GFP N PK 24 c [20]
COS-7 GFP N – 24 n [78]
Untagged N – 48 n, pn, pef [81]
FLAG N – ? pn, m [13]
HepG2 FLAG N – 48 n [57]
MDM CMV N – 24 n, pn Transduction [62]
GFP C – 6 n [16]
Alexa-488 N – 48 n EC Vpr [63]
Jurkat Untagged –– 48 n, pn [61]
Perivascular macrophage Tg N – n Tg-Vpr mice [71]
U-87 MG ECFP N – 24 n, c [7]
A summary of studies reported in the literature about Vpr localization patterns in different cell lines is reported. Most of the studies have been accomplished in
HeLa and 293T cells and results have differed according to the tagging system employed, the posttransfection time point, and/or location of the tag (at either
the amino- or carboxyl-terminus). Very few studies have utilized other cell types relevant to HIV-1 pathogenesis. Abbreviations are as follows: CMV:
cytomegalovirus, EC: extracellular, ECFP: enhanced cyan fluorescent protein, EYFP, enhanced yellow fluorescent protein, FLAG: DYKDDDDK (proprietary tag, Sigma,
St. Louis, MO), b-gal: galactosidase, GFP: green fluorescent protein, GST, glutathione S-transferase, HA: hemagglutinin, IRES: internal ribosomal entry site, PK:
pyruvate kinase, PKA: protein kinase A, Tg: transgenic, VV: vaccinia virus. Localization patterns are abbreviated as follows: n: nuclear, pn: perinuclear, pef: punctate
extranuclear foci, c: cytoplasmic, m: mitochondrial.
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efficiency to facilitate examination of specific Vpr func-
tional properties. Relevant to this experimental strategy,
previous studies have suggested that cellular phenotype
may alter the requirement for Vpr during the course of
productive viral replication [8-11]. On the basis of these
observations, we hypothesized that cellular phenotype
and hence specific interactions with selected cellular pro-
teins alter the pattern of Vpr localization. In this regard,
we examined the intracellular localization of Vpr follow-
ing transfection of a spectrum of cellular targets repre-
sentative of cell populations during the course of HIV-1
disease. To this end, we have used as a tagging system a
Zoanthus green (ZsGreen) fluorescent protein, which has
been previously shown to have higher intracellular stabi-
lity than enhanced green fluorescent protein (EGFP) [43].
For comparative purposes, the localization of each Vpr
construct was first examined in HEK 293T cells. Cells
were transfected by the calcium phosphate method and
intracellular localization was evaluated by deconvolution
immunofluorescence microscopy at 24 h after transfec-
tion. While ZsGreen protein does not show preferential
localization (Figure 1A), Vpr tagged with ZsGreen either
at the N-terminus (ZsGreen-Vpr) or C-terminus (Vpr-
ZsGreen) (Figure 1B and 1C, respectively) was located
primarily at the nuclear envelope, as well as in speckles
within the nucleus and cytoplasm. These findings con-
firm previous Vpr localization studies in this cell type
[27,44,45], unlike a study wherein EGFP-Vpr and Vpr-
EGFP localization patterns were found to differ in HEK
293T cells [27]. In addition, Vpr-induced localized her-
niations were observed at the nuclear envelope, as pre-
viously reported [46]. We next examined whether other
HIV-1 proteins could affect Vpr localization as a more
representative scenario of in vivo HIV-1 infection. To
this end, 293T cells were cotransfected with the Vpr- and
Env-deficient pNL4-3R
-E
- molecular clone along with the
ZsGreen-Vpr plasmid. Localizations of the ZsGreen pro-
tein alone as well as that of ZsGreen-Vpr were not per-
turbed by the presence of the viral proteins expressed
from the molecular clone (Figure 2A and 2B). Also, the
addition of the envelope protein in the cotransfection
reaction did not alter Vpr localization in 293T cells
(Figure 2C). Because the molecular clone utilized in these
studies was also Nef-deficient ,t h ep r e s e n c eo ft h i sv i r a l
protein was also assessed to determine whether it would
have any impact on Vpr localization. While DsRed2
was uniformly distributed intracellularly (Figure 3A),
Nef-DsRed2 was found primarily within the cytoplasm
(Figure 3B), which confirms previously reported obser-
vations [47-49]. Because both Vpr and Nef have been
cloned in frame with two different color-emitting pro-
teins, studies were performed to confirm that neither of
the fluorescently labeled proteins alters the localization
pattern of the other protein. Indeed, both ZsGreen and
D s R e d 2a r ee v e n l yp r e s e n tt h roughout the intracellular
compartment (Figure 3C). Cotransfection of ZsGreen-
Vpr and Nef-DsRed2 clearly demonstrated that both viral
proteins maintain their typical localization patterns
(Figure 3D), without interfering with the localization of
the other protein. These results prompted us to further
investigate possible variations in the intracellular localiza-
tion of only the HIV-1 Vpr protein without any other
viral proteins cotransfected in cis or in trans with the
Vpr-containing plasmid.
Vpr localization pattern in human blood-borne cells
T cells and cells of the monocyte-macrophage lineage pre-
sent in the human PB and regional lymph nodes are com-
monly infected by HIV-1 during the course of HIV/AIDS
and constitute the majority of the HIV-1-infected cells in
these compartments. In this regard, the Jurkat and U-937
human cell lines have been used as cells representative of
CD4
+ T lymphocytes and monocytic cells. As shown in
Figure 4, ZsGreen uniformly localized throughout the
intracellular environment of Jurkat cells (Figure 4A),
whereas both N- and C-terminally ZsGreen-tagged Vpr
proteins were found to accumulate exclusively as foci
within the cytoplasm (Figure 4B and 4C). In contrast,
when we analyzed U-937 cells, while ZsGreen protein
alone maintained an even distribution intracellularly
(Figure 5A), both ZsGreen-Vpr and Vpr-ZsGreen were
distributed predominantly inside the nucleus, with a small
amount of Vpr dispersed within the cytoplasm (Figure 5B
and 5C). Similar to HEK 293T cells, the location of the tag
does not alter the pattern of Vpr localization. However,
the localization pattern is remarkably different among
these three cell types: (1) mainly around the nuclear envel-
ope (293T), (2) intranuclear (U-937), and (3) punctate
cytoplasmic (Jurkat). Because all blood-borne cells are
derived from the BM, studies were designed to determine
how Vpr distributed within a progenitor cell population to
ascertain whether there are basic differences in Vpr accu-
mulation in a cellular phenotype similar to that encoun-
tered in the early stages of BM differentiation. As one
approach to examine this question, the TF-1 human BM
progenitor cell line was transfected with ZsGreen-tagged
Vpr constructs as described in “Methods.” TF-1 cells have
been shown to exhibit two morphologies: a more fre-
quently encountered round-shaped one similar to lympho-
cytes or monocytes and a less frequent elongated one,
comparable to a fibroblastic morphology. In TF-1 cells,
ZsGreen protein was present throughout the cellular com-
partment (Figure 6A), whereas both types of Vpr were dis-
tributed prevalently at the nuclear rim, with scarce
speckled structures found both intranuclearly and within
the cytoplasm (Figure 6B and 6C). This localization
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morphology (round or elongated) (data not shown).
Vpr localization pattern in human astroglial cells
In addition to the PB and peripheral lymphoid tissues,
HIV-1-infected cells have been shown to increase in a
number of end organs such as the mucosal tissues, lungs,
kidneys, and the brain [50-54]. Among CNS-resident cells,
microglia and infiltrating monocytes are the cells most
commonly found to be productively infected by HIV-1
[34,35,55], although recently the role of astrocytes has
been reconsidered owing not only to their abundance but
also to an underestimation of their infection rate [36,37].
Neurons, although sensitive to both HIV-1-induced and
indirect effects, are still considered to be refractile to
infection by the virus. Owing to the absence of an ideal
human microglial cell line and to the increasing evidence
of the importance of astrocytes in HIV-1-related neuro-
pathogenesis, we focused our attention on astrocytic cells
and investigated HIV-1 Vpr localization in two astro-
glioma cell lines: U-373 MG and U-87 MG. Nucleofection
studies show that while ZsGreen preserves a global uni-
form distribution in both cell lines (Figures 7A and 8A),
ZsGreen-Vpr and Vpr-ZsGreen are found primarily at the
nuclear envelope and around nucleoli, although a distinct
presence is noticeable around the nuclear rim, probably
coinciding with the endoplasmic reticulum (Figure 7B and
7C and Figure 8B and 8C). In addition, typical localized
herniations could be observed at the nuclear envelope
similar to those previously observed in 293T cells.
Figure 1 ZsGreen-tagged Vpr proteins localize at the nuclear envelope and in cytoplasmic speckles within 293T cells.( A )Z s G r e e n
protein was evenly distributed throughout the cell, with no preference of accumulation in any intracellular organelle. (B) ZsGreen-Vpr and (C)
Vpr-ZsGreen show preferential accumulation at the perinuclear boundaries and punctate intranuclear accumulation. Dispersed presence was
detectable in the cytoplasm along with localized herniations at the nuclear envelope. The position of the tag (either at the N- or C-terminus) did
not influence the Vpr localization pattern. For all figures, the first column represents DAPI (nuclear) staining, the second column represents the
FITC (green) channel, and the third column is the merged view where the two channels overlap, in order to give a complete view of the
intracellular localization. All figures are shown as cross-sectional views and are representative of the entire cell population observed.
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HIV-1 Vpr is a viral regulatory protein that acts at many
points along the viral life cycle. Vpr intracellular localiza-
tion and dwell time in different compartments depend on
the intrinsic molecular interactions exerted between dis-
tinctive Vpr domains and other viral or cellular partner
proteins (for a review, see [56]). These interactions depend
not only on the stage of the viral life cycle but also on the
expression of intracellular binding partners, which are ulti-
mately differentially regulated in selected cellular pheno-
types. Indeed, HIV-1 Vpr has been shown to be essential
to productively infect cells of the monocyte-macrophage
lineage [8-10], whereas its presence is dispensable for
replication within lymphocytes [11]. This could suggest
the presence of different host cellular factors differentially
expressed in the two cell types, which Vpr relies upon, or
of negative regulatory factors in lymphocytes (absent in
monocytes) that eliminate the requirement for Vpr with
respect to productive replication.
In the studies described herein, different cellular micro-
environments were examined for their potential impact
on the pattern of Vpr localization observed under
selected experimental conditions. To this end, six differ-
ent cell lines representative of important HIV-1 targets
within the PB, BM, and CNS were explored. We deter-
mined that the location of the ZsGreen-emitting protein
at either the N- or C-terminus did not affect Vpr locali-
zation in HEK 293T cells, unlike a previously reported
study performed with the EGFP [27]. Indeed, as reported
by several independent studies [18,44,57-60], Vpr is
found predominantly at the nuclear rim and to a lesser
extent in speckles present both inside the nucleus and
within the cytoplasm. In addition, localized herniations
were detected at the nuclear envelope in HEK 293T cells,
as has been previously reported by other investigators
[46]. The herniated areas may facilitate shuttling or leak-
age of Vpr molecules between the nuclear and cytoplas-
mic compartments. To model a more relevant in vivo
scenario, studies are underway to determine whether the
presence of the other HIV-1 viral proteins could influ-
ence Vpr localization by cotransfection studies. The
results have clearly indicated that none of the other viral
Figure 2 Cotransfection with other HIV-1 viral proteins does not change Vpr localization pattern within 293T cells. (A) The ZsGreen
expression vector cotransfected with a Vpr- and Env-deficient (pNL4-3R
-E
-) molecular clone maintains its uniform ZsGreen localization
throughout the intracellular environment. The ZsGreen-Vpr expression vector cotransfected with pNL4-3R
-E
- molecular clone without (B) or with
the envelope protein (C) preserves the same localization pattern as ZsGreen-Vpr (Fig. 1). The first, second, and third columns represent DAPI,
FITC, and merged views, respectively. Each figure represents a cross-sectional view of the cell and is representative of the entire cell population
observed.
Ferrucci et al. Virology Journal 2011, 8:397
http://www.virologyj.com/content/8/1/397
Page 6 of 16proteins, added either singly or in combination, altered
the intracellular location of Vpr. Studies then proceeded
to examine Vpr localization of Vpr within the two
human cell lines representative of the main cellular tar-
gets for HIV-1 within the PB. In this respect, our studies
clearly demonstrated that the CD4
+ T-lymphocytic Jurkat
cells exhibited primarily a cytoplasmic localization con-
sisting of punctate cytoplasmic foci. These results partly
contrast with published results employing a Jurkat cell
line [61], although with a different clone than the one uti-
lized in the present study. In this regard, Bolton and cow-
orkers demonstrated primarily nuclear localization of
Vpr, with small amounts of Vpr localized to the cyto-
plasm, although other cells within the same population
showed a more perinuclear localization pattern. However,
t h ed i f f e r e n c eb e t w e e nt h et w os t u d i e sm a yr e l a t et ot h e
difference in the posttransfection time at which cells
were analyzed (24 h after transfection herein as com-
pared with 48 h in the previous study [61]), although in
an additional study, a Vpr peptide (residues 52-96) added
extracellularly to lymphocytes and lymphoblasts was dis-
tributed exclusively within the cytoplasm [13]. In contrast
to T cells, within a promonocytic U-937 cell line, Vpr
appears to accumulate exclusively within the nucleus, as
also shown in one study employing transfected mono-
cyte-derived macrophages [16]. Two additional indepen-
dent studies have also found a nuclear pattern in
monocyte-derived macrophages either transduced by a
Vpr-containing adenovirus vector [62] or treated with an
extracellular synthetic Vpr [63].
Hematopoietic differentiation occurs within the BM,
after which time cells leave the BM and eventually enter
the peripheral circulation. As one approach to model this
developmental process, Vpr localization studies were per-
formed in a human CD34
+ BM progenitor cell line to
determine whether this was similar to the pattern observed
in either differentiated cell type (lymphocytes or mono-
cytes). TF-1 cells showed perinuclear localization, with
accumulation involving punctate foci both within the
nucleus and likely at the endoplasmic reticulum, a pattern
Figure 3 ZsGreen-Vpr localization pattern in 293T cells is not affected by addition of Nef protein. (A) DsRed2, similar to ZsGreen protein,
was uniformly distributed throughout the intracellular environment. (B) Nef-DsRed2 displays a cytoplasmic accumulation, being completely
excluded from the nuclear compartment. (C) As a control, ZsGreen and DsRed2 expression vectors were cotransfected and both localized evenly
in the intracellular environment (as evidenced by the overlapping yellow staining). (D) When both ZsGreen-Vpr and Nef-DsRed2 expression
vectors were cotransfected, neither protein’s localization pattern (perinuclear and cytoplasmic, respectively) was altered. In parts A and B, the first,
second, and third columns are DAPI, FITC, and merged view, respectively. In parts C and D, the first, second, third, and fourth columns represent
DAPI, FITC (green), TRITC (red), and merged views, respectively. Each figure represents a cross-sectional view of the cell and is representative of
the entire cell population observed.
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cells than either the lymphocytic or monocytic cell line.
These observations suggest that cellular differentiation
and/or activation results in changes in the pattern of Vpr
accumulation. These changes may be closely linked to dif-
ferentiation- and/or state-of-activation-dependent altera-
tions in the presence or modification of intracellular
factors regulated during the differentiation process. Indeed,
the Vpr localization pattern in TF-1 was clearly different
from that found within representative cell lines of CD4
+
T-lymphocytic or monocytic origin.
The CNS, although anatomically compartmentalized, is
surveyed by cells involved in immune surveillance and is
also breached by potentially neurotoxic substances and/
or cells infected by any of a number of infectious agents,
including HIV, particularly under circumstances of
pathogenic insult. Within the CNS, HIV-1 preferentially
targets microglia, trafficking monocyte-derived macro-
phages and brain microvascular endothelial cells, and, to
a lesser extent, astrocytes, which likely represent an
important CNS reservoir simply based on their numbers.
Owing to the lack of a reliable microglial cell line, we
have investigated two different types of astroglioma cell
lines (U-373 MG and U-87 MG) and found that Vpr dis-
played a similar localization pattern in both. A predomi-
nant accumulation around the nuclear envelope was
observed, although Vpr also localized within the cyto-
plasm and to a lesser extent in the nucleus and around
the nucleoli. This localization pattern was most similar to
that observed in one previous study performed in U-87
MG cells [7].
The differential localization patterns we observed in the
aforementioned cell lines indicate that the cellular phe-
notype affects the intracellular distribution of Vpr and
point to a role that Vpr might play in each cell type. In
this regard, a nuclear localization pattern in monocyte-
derived macrophages may reflect a role Vpr could have
as a transcription factor. This possibility is substantiated
Figure 4 ZsGreen-Vpr localizes exclusively in the cytoplasm within Jurkat lymphocytic cells. While control ZsGreen protein (A) was evenly
distributed, both ZsGreen-Vpr (B) and Vpr-ZsGreen (C) were found in speckles only within the cytoplasmic compartment, completely excluded
from the nucleus. First, second, and third columns are DAPI, FITC, and merged views, respectively. Each figure represents a cross-sectional view
of the cell and is representative of the entire cell population observed.
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ity for Vpr-deficient molecular clones in cells of the
monocytic lineage. Conversely, a cytoplasmic accumula-
tion in CD4
+ T lymphocytes could denote a more active
participation in later phases of the viral cycle, such as vir-
ion incorporation or as a secreted protein. In the former
case, the presence of Vpr within the cytoplasm could
reflect an increased interaction with p6 proteins as more
viral transcription takes place. Indeed, within CD4
+
T cells, Vpr is known to synergize with Nef in activating
nuclear factor of activated T cells (NFAT)-dependent
and cyclic AMP response element (CRE)-directed tran-
scription [64]. This leads to increased viral genome
production owing to the presence of NFAT and CRE-
responsive elements within the HIV-1 promoter. In the
latter case, because Vpr has been shown to be released
from Jurkat cells [65] and extracellular Vpr has been
detected within the blood of HIV-1-infected patients
[66,67], this cell type could be responsible for secretion
of Vpr within the PB compartment, given the Vpr cyto-
plasmic distribution in this T-cell line. However, it
remains possible that Vpr release is just the consequence
of Vpr’s apoptogenic nature rather than the result of an
active secretion process (for a review, see Ferrucci et al.,
2011, manuscript in press). A further explanation of the
different intracellular localization of Vpr between Jurkat
and U-937 cells could lie in the differential expression of
Vpr binding partners between the two cell lines. For
instance, Vpr is known to interact with UNG, a uracil
DNA glycosylase repair enzyme [68], whose gene gives
rise to UNG1 and UNG2 by alternative splicing, found
cytoplasmically and nuclearly, respectively [69]. A possi-
ble phenotype-specific differential expression of either
form in the two cell lines, such that UNG1 were found
Figure 5 Localization of ZsGreen-Vpr within U-937 promonocytic cells is predominantly intranuclear. (A) ZsGreen control protein localizes
uniformly intracellularly, while both ZsGreen-Vpr (B) and Vpr-ZsGreen (C) are similarly distributed within the nucleus, with a very low level
accumulation in the cytoplasm, unlike Jurkat cells. The first, second, and third columns represent DAPI, FITC, and merged views, respectively. All
figures denote a cross-sectional view of the cell. Similar results have been obtained in triplicates.
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Page 9 of 16predominantly in Jurkat (or CD4
+ T lymphocytes) and
UNG2 primarily in U-937 (or monocytic cells), could
then explain why Vpr localizes within the cytoplasm or
the nucleus, respectively. Other important intracellular
host factors Vpr has been shown to interact with are the
Sp1 and CCAAT enhancer binding proteins (C/EBP)
[70], which are differentially regulated in several different
cell lines. For instance, the overabundance of C/EBP in
U-937 monocytic cells compared with Jurkat lympho-
cytes (Y. Liu and B. Wigdahl, unpublished observations)
could explain a more nuclear localization of Vpr in the
former cell line. Conversely, a more perinuclear localiza-
tion in the other cell lines examined could be the cause
of decreased affinity with the aforementioned proteins,
rather a stronger binding for factors such as importin-a
for which Vpr was shown to interact [4,18,21].
Within the CNS, infected infiltrating CD4
+ T lympho-
cytes and trafficking monocytes play an important role
in HIV-1 pathogenesis by continually seeding virus into
the CNS. Because Vpr has been found in a soluble form
within the cerebrospinal fluid of HIV-1-infected patients
[67], these two cell types could participate in the release
process both within the PB and CNS compartments. In
this regard, after either lymphocytes or monocytes
infected with HIV-1 and expressing Vpr have crossed
the blood-brain barrier it is possible that intra-CNS
cytokines or other signaling molecules induce changes
in the levels and activities of intracellular factors. In
turn, these may play a role in altering the intracellular
accumulation of Vpr, which ultimately leads to func-
tional changes in these infected cell populations in ways
that may alter the course of HIV-1-associated neurologic
Figure 6 ZsGreen-tagged Vpr localizes at the perinuclear rim within TF-1 bone marrow progenitor cells. (A) ZsGreen protein localized
uniformly intracellularly (including nucleoli). (B and C) Both ZsGreen-Vpr and Vpr-ZsGreen display an intracellular localization pattern similart o
that observed in HEK 293T cells. Vpr is found primarily at the nuclear envelope, although a low level of accumulation was also found in speckles
both in the nucleus and in the cytoplasm. Similar to 293T cells, localized herniations were observed at the nuclear rim. The first, second, and
third columns represent DAPI, FITC, and merged views, respectively. All figures denote a cross-sectional view of the cell and are representative of
the entire cell population.
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Page 10 of 16disease. In addition, given the extensive amount of Vpr
in the cytoplasm of astrocytes and because of their
number within the CNS, these cells also contribute to
Vpr release either through a regulated secretory process
or through necrosis or apoptosis. Among other CNS-
resident cells, brain perivascular and parenchymal
microglial cells could also contribute to seeding viral
infection within the CNS. Only one study has been pub-
lished that showed a predominant nuclear localization
of Vpr in these two cell types, although the study was
performed in Vpr-transgenic mice [71].
Conclusion
The present study is the first to extensively analyze and
compare Vpr localization in different cell types relevant
to HIV-1 infection. These results summarize and amplify
the breadth of knowledge available to date concerning
Vpr intracellular localization and impact on HIV-1
pathogenesis (Table 1). We observed different localiza-
tion patterns in different cell types that represent primary
targets of HIV-1, which may relate to differences in Vpr
function within each cell type. Future studies employing
different primary HIV-1 target cells are needed to clearly
discern how cellular phenotypes affect Vpr intracellular
trafficking. However, it must be asserted that most of the
reported studies, as well as the studies reported herein,
have employed transfection methods, which generally
involved overproduction of the desired protein. This sce-
nario more closely reflects an acute cellular infection,
with abundant protein synthesis and viral production.
It will be informative to examine Vpr localization at dif-
ferent time points in cells infected with Vpr-containing
virus, as this would more accurately model the in vivo
environment. This type of model would also facilitate
studies to determine how the recognition of specific
amino acid residues and localization signals could be
Figure 7 In U-373 MG astroglioma cells, ZsGreen-Vpr shows a localization pattern similar to HEK 293T cells. (A) While ZsGreen protein
clearly distributed throughout the intracellular environment, both ZsGreen-Vpr (B) and Vpr-ZsGreen (C) were found mainly at the nuclear
envelope, along with localized herniations around the nuclear membrane, and in speckles within the nuclear compartment. First, second, and
third columns are DAPI, FITC, and merged views, respectively, and each figure represents a cross-sectional view of the cell. These figures are
representative of the entire cell population observed.
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Page 11 of 16altered in different cell types. For instance, nuclear locali-
zation signals could be masked in different cellular envir-
onments by interactions with host cell factors not
present in other cells. It is indeed possible to hypothesize
that organelle localization signals might be cell type-
dependent, owing either to a masking effect or to differ-
ent protein-protein interactions in distinct cell types.
Another approach would be to employ a cell line stably
transfected with a Vpr-expressing plasmid and analyze
how Vpr localization pattern varies during latency or
after administration of stimuli known to rescue produc-
tive viral replication.
Methods
Cell lines
The human cell lines utilized in the protein localization stu-
dies included the human endothelial kidney (HEK) 293T
(fibroblast), Jurkat (CD4
+ T cells), U-937 (promonocytic),
U-87 MG and U-373 MG (both of astroglioma origin), and
TF-1 (BM progenitor). The HEK 293T cell line was grown
in 1 × Dulbecco modified Eagle medium (DMEM) supple-
mented with heat-inactivated fetal bovine serum (FBS)
(10%), antibiotics (penicillin and streptomycin, at a concen-
tration of 0.04 mg/mL each), glucose (4.5 g/mL), sodium
pyruvate (1 mM), and HEPES (10 mM). The human T-cell
line (Jurkat), the human monocytic cell line (U-937), and
the erythromyeloid precursor cell line (TF-1) were all
g r o w ni nR P M I - 1 6 4 0( R o s w e l lP a r kM e m o r i a lI n s t i t u t e )
media. Media for Jurkat cells were supplemented with heat-
inactivated FBS (10%), sodium bicarbonate (0.05%), and
antibiotics (penicillin, streptomycin, and kanamycin at
0.04 mg/mL each). Media for U-937 and TF-1 cells were
supplemented with heat-inactivated FBS (10%), antibiotics
(penicillin and streptomycin, at a concentration of 0.04 mg/
mL each), glucose (4.5 g/mL), sodium pyruvate (1 mM),
and HEPES (10 mM). TF-1 cells were also supplemented
with recombinant granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) (2 ng/mL). The human astroglioma
cell lines (U-87 MG and U-373 MG) were grown in 1 ×
DMEM supplemented with heat-inactivated FBS (10%),
penicillin and streptomycin (at a concentration of 0.04 mg/
mL each), kanamycin sulfate (0.04 mg/mL), and sodium
bicarbonate (final concentration 0.05%). All cells were
maintained at 37°C in 5% CO2 at 90% relative humidity.
Figure 8 U-87 MG displays a localization pattern of ZsGreen-tagged Vpr similar to U-373 MG astroglial cells. ZsGreen protein was
uniformly distributed intracellularly. ZsGreen-Vpr (B) and Vpr-ZsGreen (C) localized at the nuclear envelope, along with a speckled formation
intranuclearly. An accumulation around the nucleolar rim could also be observed, as well as localized herniations at the nuclear envelope. A
conspicuous amount was also noticeable at the immediate outer layer of the nuclear envelope, possibly coinciding with the endoplasmic
reticulum. The first, second, and third columns represent DAPI, FITC, and merged views, respectively. All figures denote a cross-sectional view of
the cell and are representative of the entire cell population.
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HIV-1 Vpr was obtained by standard PCR amplification
techniques from the noninfectious pNL4-3R
+E
- molecular
clone (obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH, provided by Dr. Nathaniel Landau [8,55]). To clone
ZsGreen-Vpr and Vpr-ZsGreen, pZsGreen-C1 and
pZsGreen-N1 vectors (Clontech, Mountain View, CA)
were used to place the green fluorescent protein at either
the amino- or carboxyl-terminus of the viral protein,
respectively. The following PCR primers were employed:
5’-GATCTCGAGCTATGGAACAAGCCCCAGAAGACC
and 5’-GACGTGAAGCTTCTAGGATCTACTGGCTCC
(forward and reverse to clone ZsGreen-Vpr) and 5’-
ATAGGATCCGCCACCATGGAACAAGCCCCAGAA-
GACC and 5’-CGAACCGGTCCACCTGATCTACTG
GCTCC (forward and reverse to clone Vpr-ZsGreen). The
different primers harbor specifically engineered restriction
endonuclease cleavage sites as underscored in each of the
sequences provided. Forward and reverse primers to clone
ZsGreen-Vpr contain XhoIa n dHindIII cleavage sites,
respectively, whereas forward and reverse primers for Vpr-
ZsGreen include BamHI and AgeI, respectively. The for-
ward primer to the PCR construct (Vpr-ZsGreen) also
incorporated a consensus Kozak sequence (in bold) prior
to the Vpr ATG to aid in initiation of the translation pro-
cess [72]. PCR-amplified Vpr products and ZsGreen-
containing vectors were then digested with the respective
restriction endonucleases (Promega, Madison, WI) in a
one-step reaction for 1 h at 37°C to obtain complementary
single-stranded sequences at the ends of each product.
Cloning of Vpr products and ZsGreen-containing vectors
was then completed by overnight ligation at 4°C with T4
DNA ligase (Promega). The pNL4-3R
-E
- molecular clone
(with a four-basepair insertion to inactivate the Vpr coding
sequence) was obtained as described for pNL4-3R
+E
-.
Because both the pNL4-3R
+E
- and pNL4-3R
-E
- molecular
clones are also Nef-deficient owing to the insertion of a
luciferase gene, a Nef-containing plasmid (kindly provided
by Dr. Simon Cocklin, Drexel University College of Medi-
cine, Philadelphia, PA) was utilized to clone Nef into the
pDsRed2-N1 expression vector (Clontech). Forward (5’-
ATAAAGCTTGCCACCATGGGAGGGAAGTGG) and
reverse (5’-GATGGATCCCCTCCGCAGTTCTTGAAG-
TACTCC) primers were used to PCR amplify Nef, which
include HindIII and BamHI cleavage sites, respectively.
The forward primer also contains a consensus Kozak
sequence at the 5’ end of the ATG transcriptional start
site. The PCR products and pDsRed2-N1 plasmid were
then digested with HindIII and BamHI restriction
enzymes (Promega) and ligated overnight at 4°C as
described for the Vpr-containing recombinant plasmids.
The envelope-containing plasmid was a kind gift from
Dr. Julio Martin-Garcia (Drexel University College of
Medicine, Philadelphia, PA). All cloned constructs were
confirmed by DNA sequencing (Genewiz, Inc., South
Plainfield, NJ).
Transfection studies
Exponentially growing HEK 293T cells (2 × 10
5)w e r e
seeded in each well of a 12-well plate. Four hours prior
to transfection, the cell medium was replaced and trans-
fections were performed at about 70% cell confluency
with the classical calcium phosphate method using 2 μg
of plasmid DNA (either ZsGreen control or Vpr plasmid)
mixed with CaCl2 to a final concentration 60 mM. The
CaCl2-DNA mixture was then added dropwise into a
solution of 2× HEPES-buffered saline (HBS). Following a
30-min incubation at room temperature, the CaCl2-
DNA-2× HBS mixtures were dispensed dropwise to the
cell culture monolayers. After a 5-h incubation, the cell
culture medium was replaced and the cell monolayers
were incubated for an additional 24 h prior to processing
for immunofluorescent microscopic analyses. For
cotransfection studies, the DNA mixture was a combina-
tion of Vpr, pNL4-3R
-E
- molecular clone, and envelope
and Nef plasmids in a 1:2:1:1 ratio. The calcium phos-
phate transfection method consistently produced a 50%
transfection efficiency.
For all other cell lines, transfection was performed using
a chemical/electroporation technique (nucleofection) as
described by the manufacturer (Amaxa; Lonza, Basel,
Switzerland). Briefly, 2 days prior to transfection, 10
6 sus-
pension cells (Jurkat, U-937, and TF-1 cells), passaged to
allow them a logarithmic phase growth on the day of
transfection, were washed twice in 1× phosphate-buffered
saline (PBS) and then resuspended in 100 μL nucleofector
solution containing 2 μg of plasmid DNA. The mixture
was then placed into an appropriate cuvette, the cells
nucleofected using the proprietary Amaxa device and
transferred back to a single well of a 12-well plate. For the
two adherent astroglioma cell lines, the same protocol was
used with the addition of an initial trypsinization step
prior to resuspension. Each cell line was transfected with a
different nucleofection procedure and protocol program
as follows: Jurkat (procedure V, program X-005), U-937
(procedure V, program W-001), TF-1 (procedure T, pro-
gram T-001), and two astroglioma cell lines (procedure T,
program X-001). Overall, this nucleofection method
yielded a delivery efficiency of 30-40% for both astro-
glioma cell lines and TF-1 cells, whereas Jurkat and U-937
cells yielded a delivery efficiency of about 5%.
Immunofluorescence and deconvolution microscopy
HEK 293T cells were grown on poly-lysine-coated cover-
slips and transfected in situ, whereas all other cells were
first nucleofected and then transferred to poly-lysine-
coated coverslips immediately after transfection. For all
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Page 13 of 16immunofluorescence studies, cells were harvested 24 h
after transfection, washed twice with PBS, and fixed in
2% paraformaldehyde for 20 min. Cells were then stained
with 4’,6-diamidino-2-phenylindole (DAPI; Invitrogen,
Carlsbad, CA) and mounted on slides. Cells were washed
three times in between each step and imaged with a
deconvolution microscope (Olympus, Center Valley, PA).
For all cell types examined, a minimum of 10 fields were
examined at 40× magnification. Images shown at higher
magnifications are representative of the entire cell popu-
lation with a minimum of 20 different sectioned planes
examined at a distance of 0.2 μm and representative
images captured for the different channels (DAPI, fluor-
escein isothiocyanate [FITC], and/or tetramethylrhoda-
mine isothiocyanate [TRITC]). Deconvolution using the
nearest-neighbor algorithm was applied to all images in
order to deblur scattered light from neighboring planes
and improve the image contrast. Deconvolved planes
were also stacked to yield a three-dimensional recon-
struction of volume images in order to confirm Vpr
localization.
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BM: bone marrow; C/EBP: CCAAT enhancer binding proteins; CNS: central
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